foxo4-dri peter de keizer – Longevity Med Summit Peter De Keizer, Scientific Founder,
Peter De Keizer, Scientific Founder, Co Managing Director, Assistant Professor eMedEvents The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Senolytics: Courageous approach to fight aging and cancer FOXO4 DRI Peptide 10 mg Eternal youth within reach by targeting senescent cells?
Pay in 4 interest-free payments of $6.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



